Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Theravance telavancin NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Theravance submits telavancin for treatment of complicated skin and skin structure infections. The South San Francisco biopharmaceutical company is requesting a priority review for the injectable lipoglycopeptide antibiotic, giving it an estimated user fee date of June 7. The NDA is based on the firm's ATLAS I and ATLAS II trials, which Theravance says were "the largest clinical program ever" in CSSSIs. The company is collaborating with Astellas on development and commercialization of telavancin...

You may also be interested in...

Astellas’ Potential Zelnorm Competitor Ramosetron Poised For Phase III Trials

Astellas Pharmaceuticals could enter U.S. Phase III studies with its diarrhea-predominant irritable bowel syndrome agent YM060 (ramosetron) as soon as the first half of 2008, Executive VP Toshinari Tamura told analysts during a third quarter earnings call Feb. 1

Warning Letter Close-Outs – March 2020

The US FDA released five device-related close-out letters in March.

Medicines Must Be Designated As Priority Items, Says IGBA

Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts